Skip to content
Screener

Net Change in Cash at other companies

Arvinas logo
ArvinasARVN
-$55.6M-185%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$19.6M-108%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-$69.76M-672%
Septerna, Inc. logo
Septerna, Inc.SEPN
-$49.12M-74.5%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$74.44M-49.3%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$320.25M+1,018%

Other financials

Income statement

See full
Revenue$9.0M-79.5%
Operating income-$94.2M-95.0%
Net income-$89.5M-106%
EPS (diluted)-$0.81-55.8%

Balance sheet

See full
Cash & equivalents$68.7M-19.4%
Total debt$58.1M+12.0%
Total equity$402.6M-10.0%
Total assets$535.5M-9.5%

Cash flow

See full
Operating cash flow-$96.6M-52.9%
CapEx$1.9M-27.6%
Free cash flow-$98.5M-49.6%

Valuation

See full
Market cap$2.62B+227%
Enterprise value$2.61B+240%
P/S71.2×+62.1×

Profitability

See full
Operating margin-982.4%-1,538pp
Net margin-928.4%-1,403pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-80.3%+113pp
Debt / equity0.1×0.0×
Current ratio6.3×-0.5×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.

Filed
Jul 9, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001549595-26-000040
Line itemSix Months Ended May 31, 2026Six Months Ended May 31, 2025
Proceeds from issuance of common stock under employee stock purchase plan1,5961,252
Proceeds from issuances of common stock in “at the market” financing, net of issuance costs18,004
Net cash provided by financing activities20,0411,479
Net decrease in cash, cash equivalents and restricted cash(179,275)(25,737)
Cash, cash equivalents and restricted cash at beginning of period247,928110,898
Cash, cash equivalents and restricted cash at end of period$68,653$85,161
Supplemental disclosures of non-cash investing and financing activities:
Additions to property and equipment included in accounts payable and accrued expenses and other current liabilities$314$1,082

Item 1. Financial Statements (Unaudited)

FAQ

What is Nurix Therapeutics, Inc.'s net change in cash?
Nurix Therapeutics, Inc. (NRIX) reported net change in cash of -$3.51M in Q1 2026.
How has Nurix Therapeutics, Inc.'s net change in cash changed year-over-year?
Nurix Therapeutics, Inc.'s net change in cash decreased by 142.1% year-over-year, from $8.34M to -$3.51M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Nurix Therapeutics, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude